Clinuvel Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	36.17	35.64	30.6	20.88	24.73
Depreciation & Amortization	1.15	1.09	0.74	0.72	0.82
Loss (Gain) From Sale of Assets	-	-	-	0.03	0.09
Stock-Based Compensation	2	6.11	8.99	6.12	2.6
Other Operating Activities	-0.42	0.67	-0.21	0.17	1.56
Change in Accounts Receivable	-1.22	-4.02	-6.01	-0.11	-9.48
Change in Inventory	1.81	-1.11	-7.69	1.35	-1.9
Change in Accounts Payable	2.84	-0.65	4.51	-1.56	-
Change in Income Taxes	-1.3	-0.24	8.81	7.18	0.1
Change in Other Net Operating Assets	-0.87	0.07	-1.41	-0.97	-0.14
Operating Cash Flow	41.1	37.05	36.91	39.87	19.26
Operating Cash Flow Growth	10.91%	0.38%	-7.42%	107.00%	35.76%
Capital Expenditures	-0.3	-5.58	-1.03	-0.43	-0.85
Investment in Securities	-47.42	-23.46	-30.82	-	-
Investing Cash Flow	-47.72	-29.03	-31.85	-0.43	-0.85
Long-Term Debt Repaid	-0.18	-0.35	-0.26	-0.27	-0.2
Net Debt Issued (Repaid)	-0.18	-0.35	-0.26	-0.27	-0.2
Issuance of Common Stock	0.19	4.16	-	-	-
Repurchase of Common Stock	-0.44	-4.91	-	-	-
Common Dividends Paid	-2.5	-2.47	-1.98	-1.24	-1.24
Other Financing Activities	-	-	-	-	-0.04
Financing Cash Flow	-2.94	-3.57	-2.24	-1.5	-1.48
Foreign Exchange Rate Adjustments	2.38	-1.14	1.66	0.88	-0.98
Miscellaneous Cash Flow Adjustments	0	-	-	-	-
Net Cash Flow	-7.18	3.31	4.48	38.82	15.94
Free Cash Flow	40.8	31.48	35.88	39.44	18.41
Free Cash Flow Growth	29.61%	-12.28%	-9.01%	114.25%	38.41%
Free Cash Flow Margin	42.94%	35.70%	45.82%	60.01%	38.10%
Free Cash Flow Per Share	0.81	0.62	0.69	0.76	0.36
Cash Interest Paid	-	-	-	-	0.04
Cash Income Tax Paid	15.73	15.65	7.74	-	-
Levered Free Cash Flow	29.93	23.45	32.33	33.25	8.06
Unlevered Free Cash Flow	32.72	26.23	34.33	34.67	9.07
Change in Working Capital	2.2	-6.44	-3.22	11.96	-10.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.